Gastric emptying: difference between revisions
Diff·revision 9 → 10·02:20, 13 Jan 2025
Difference between revision 9 and revision 10 of Gastric emptying. 3 lines changed; the page grew by 660 bytes.
| Revision 9 — 22:05, 14 Dec 2024 SatietySunniva (talk) give the fasting and postprandial concentrations with the assay named 3,976 bytes +140 | Revision 10 — 02:20, 13 Jan 2025 GsCouplingGil (talk) add the citation for the co-secretion finding 4,636 bytes +660 | ||
|---|---|---|---|
| 25 | The magnitude depends on the exposure profile. A short-acting agonist producing peaks and troughs delays emptying strongly at each peak; a continuously present long-acting agonist produces a delay that diminishes over weeks. The mechanism of that attenuation is thought to be receptor desensitisation on the relevant neurons, and it is one of the clearest examples of tachyphylaxis in incretin pharmacology.{{r|marathe2013}} | 25 | The magnitude depends on the exposure profile. A short-acting agonist producing peaks and troughs delays emptying strongly at each peak; a continuously present long-acting agonist produces a delay that diminishes over weeks. The mechanism of that attenuation is thought to be receptor desensitisation on the relevant neurons, and it is one of the clearest examples of tachyphylaxis in incretin pharmacology.{{r|marathe2013}} |
| 26 | 26 | ||
| + | 27 | Three clinical consequences follow. First, postprandial glucose control is contributed to differently by short- and long-acting agents.{{r|nauck2016}} Second, nausea correlates with the degree of delay, and the attenuation of the delay tracks the attenuation of nausea. Third, and more recently recognised, residual gastric contents after conventional fasting periods have prompted revised preoperative guidance; see [[Aspiration risk under anaesthesia]]. | |
| + | 28 | ||
| 27 | == References == | 29 | == References == |
| 28 | {{reflist}} | 30 | {{reflist}} |
| ⋮ | ⋮ | ||
| 30 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 32 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 31 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> | 33 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> |
| + | 34 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> | |
| 32 | 35 | ||
| 33 | == See also == | 36 | == See also == |